September 28, 2021

Power Factor Corrector Market to Grow by CAGR of 4.37% During 2020-2028 Globally; Rising Need to Reduce Energy Consumption to Drive the Market Growth

Key Companies Covered in the Power Factor Corrector Market Research Report Are ABB Ltd., Eaton Corporation, Schneider Electric, General Electric, NAAC ENERGY CONTROLS, WEG S.A., Texas Instruments Incorporated, TDK Electronics AG, ON Semiconductor Components Industries, LLC, STMicroelectronics, and others., and other key market players. New York, Sept. 28, 2021 (GLOBE

Read More

Closing of CAD$ 300 million notes of CNH Industrial Capital Canada Ltd.

London, September 28, 2021Closing of CAD$ 300 million notes of CNH Industrial Capital Canada Ltd. CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) today announced that its indirect wholly owned subsidiary, CNH Industrial Capital Canada Ltd., has completed its previously announced private placement offering of CAD$ 300 million in aggregate

Read More

Webtel.Mobi Releases Details of Its Regulatory Compliance

Global Telephony Company is one of the most thoroughly due diligenced entities in commercial history, and applies some of the world’s most vigorous KYC and AML processes ST PETER PORT, Guernsey and NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) — To provide access to its facilities at the same rates

Read More

First-in-Class, Broad-Spectrum Nasal Spray to Prevent COVID-19 and Other Common Respiratory Illnesses Set to Begin Phase 2 Trials

— ENA Respiratory engages PPD, Inc. for Phase 2 COVID-19 post-exposure prophylaxis study and hVIVO for influenza challenge study to assess the efficacy of fast-acting nasal spray designed to boost innate immunity SYDNEY, Australia, Sept. 28, 2021 (GLOBE NEWSWIRE) — ENA Respiratory, a biotechnology company developing a first-in-class nasal spray

Read More

MRM Health Receives CTA Approval for Phase 1b/2a Trial with Next Generation Optimized Consortium Therapeutic MH002 in Ulcerative Colitis

GHENT, Belgium, Sept. 28, 2021 (GLOBE NEWSWIRE) — MRM Health, a biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announced today that they have received regulatory approval from the Federal Agency for Medicines and Health Products (FAMHP) in Belgium to start a Phase 1b/2a trial with the novel next-generation optimized

Read More